2015年呼吸系统疾病研究进展

doi:10.3969/j.issn.1004-583X.2016.02.004

临床荟萃 ›› 2016, Vol. 31 ›› Issue (2): 143-150.doi: 10.3969/j.issn.1004-583X.2016.02.004

2015年呼吸系统疾病研究进展

袁雅冬,陈烨,王丽,沈丽晓

河北医科大学第二医院呼吸与危重症医学科, 河北石家庄 050000

收稿日期:2016-01-15 出版日期:2016-02-05 发布日期:2016-04-18
通讯作者: 袁雅冬, Email;yyd1108@126.com
作者简介:袁雅冬,河北医科大学第二医院大内科主任,内科教研室主任,呼吸二科主任;中华医学会呼吸病学分会委员,中国医师协会常务委员,河北省医师协会呼吸医师分会会长;海峡两岸医药卫生交流协会呼吸病学分会常委;中国老年保健医学研究会呼吸病学分会委员;中国控制吸烟协会吸烟与疾病控制专业委员会常务委员;教育部高等学校临床医学类专业教学指导委员会委员;普通高等学校本科教学工作审核评估专家。

Clinical advances in pulmonary during 2015

Yuan Yadong, Chen Ye,Wang Li,Shen Lixiao

Department of Respiratory Medicine, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China

Received:2016-01-15 Online:2016-02-05 Published:2016-04-18
Contact: Yuan Yadong, Email;yyd1108@126.com

摘要/Abstract

摘要： 2015年随着对呼吸系统疾病的临床和基础领域研究逐渐深入,新的指南亦不断涌现,本文针对肺部感染、肺血管性疾病、间质性肺疾病、肺癌、慢性气道疾病等方面相关进展作一简单介绍。

关键词: 呼吸道感染, 肺栓塞, 肺疾病, 间质性, 肺肿瘤

Abstract: In 2015, with the development of the clinical and basic research on respiratory system disease, various guides are also inconstant update. Now, we will do simple introduction about the related development in lung infection, pulmonary vascular disease, interstitial lung disease, lung cancer, chronic bronchial disease and so on.

Key words: respiratory tract infections, pulmonary embolism , lung diseases, interstitial, lung neoplasms

中图分类号:

R563.1

袁雅冬,陈烨,王丽,沈丽晓. 2015年呼吸系统疾病研究进展[J]. 临床荟萃, 2016, 31(2): 143-150.

Yuan Yadong, Chen Ye,Wang Li,Shen Lixiao. Clinical advances in pulmonary during 2015[J]. Clinical Focus, 2016, 31(2): 143-150.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2016.02.004

https://huicui.hebmu.edu.cn/CN/Y2016/V31/I2/143

参考文献

[1] Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis, 2015, pii: S1473-3099(15)00424-7. [Epub ahead of print].
[2] Dimopoulos G,Poulakou G,Akova M,et al. Task force on management and prevention of Acinetobacter baumannii infections in the ICU[J]. Intensive Care Med,2015,41(12): 2057-2075.
[3] 陈佰义,李光辉,倪语星,等.β-内酰胺类抗生素/β-内酰胺酶抑制剂合剂临床应用专家共识[J].中华医学杂志,2015,95(48) :3887-3894.
[4] 中国医药教育协会感染疾病专业委员会,中华结核和呼吸杂志编辑委员会,中国药学会药物临床评价研究专业委员会.抗菌药物超说明书用法专家共识[J].中华结核和呼吸杂志,2015,38(6):410-444.
[5] Raja AS, Greenberg JO, Qaseem A, et al. Evaluation of Patients With Suspected Acute Pulmonary Embolism: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians[J]. Ann Intern Med,2015,163(9):701-711.
[6] Olschewski H, Kovacs. ESC guidelines 2015 on pulmonary hypertension[J].Herz,2015,40(8): 1055-1060.
[7] Maeder MT, Kleiner R, Weilenmann D. Severely worsening dyspnea after initiation of macitentan therapy for pulmonary arterial hypertension[J]. Int J Cardiol,2016,202:244-245.
[8] Hambly N, Granton J. Riociguat for the treatment of pulmonary hypertension. Expert Rev Respir Med,2015,9(6):679-695.
[9] Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension[J]. Turk Kardiyol Dern Ars,2014,42(1):78-94.
[10] Ganesh Raghu, Bram Rochwerg, Yuan Zhang, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline[J]. Am J Respir Crit Care Med,2015,192(5):644.
[11] Raghu G, Anstrom KJ, King TE Jr, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary brosis[J]. N Engl J Med,2012,366(21):1968-1977.
[12] Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary brosis[J]. Chest,2005,128(3):1475-1482.
[13] Noth I, Anstrom KJ, Calvert SB, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary brosis[J]. Am J Respir Crit Care Med,2012,186(1):88-95.
[14] Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary brosis[J]. Eur Respir J,2010,35(4):821-829.
[15] Richeldi L, du Bois RM, Raghu G, et al. INPULSIS Trial Investigators. Ef cacy and safety of nintedanib in idiopathic pulmonary brosis[J]. N Engl J Med,2014,370(22):2071-2082.
[16] Daniels CE, Lasky JA, Limper AH, et al. Imatinib-IPF Study Investigators. Imatinib treatment for idiopathic pulmonary brosis: randomized placebo-controlledtrial results[J]. AmJ Respir Crit Care Med,2010,181(6):604-610.
[17] Moorhouse RC, Webb DJ, Kluth DC, et al. Endothelin antagonism and its role in the treatment of hypertension[J]. Curr Hypertens Rep,2013,15(5):489-496.
[18] Jackson RM, Glassberg MK, Ramos CF, et al. Sildena l therapy and exercise tolerance in idiopathic pulmonary brosis[J]. Lung,2010,188(2):115-123.
[19] Zisman DA, Schwarz M, Anstrom KJ, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildena l in advanced idiopathic pulmonary brosis[J]. N Engl J Med,2010,363(7):620-628.
[20] Han MK, Bach DS, Hagan PG, et al. Sildena l preserves exercise capacity in patients with idiopathic pulmonary brosis and rightsided ventricular dysfunction[J]. Chest,2013,143(6):1699-1708.
[21] Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary brosis: an analysis of data from three randomised controlled trials[J]. Lancet Respir Med,2013,1(5):369-376.
[22] Martinez FJ, de Andrade JA, Anstrom KJ, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized trial of acetylcysteine in idiopathic pulmonary brosis[J]. N Engl J Med,2014,370(22):2093-2101.
[23] Masters GA, Temin S, Azzoli CG, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update[J]. J Clin Oncol,2015,33(30):3488-515.
[24] Ettinger DS, Wood DE, Akerley W, et al. Non-Small Cell Lung Cancer, Version 6.2015[J]. J Natl Compr Canc Netw,2015,13(5):515-524.
[25] 中华医学会呼吸病学分会肺癌学组,中国肺癌防治联盟专家组.肺部结节诊治中国专家共识[J].中华结核和呼吸杂志,2015,38(4):249-254.
[26] Vilmann P,Clementsen PF, Colella S, et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS)[J]. Endoscopy,2015,47(6):c1.
[27] Sharma A, Menche J, Huang CC, et al. A disease module in the interactome explains disease heterogeneity, drug response and captures novel pathways and genes in asthma[J]. Hum Mol Genet,201,24(11):3005-3020.
[28] Wang Y, Yang L, Li P, et al. Circulating microRNA signatures associated with childhood asthma[J]. Clin Lab,2015,61(5/6): 467-474.
[29] Sonnenschein-van der Voort, AM, Arends, LR, de Jongste, JC et al. Preterm birth, infant weight gain, and childhood asthma risk: a meta-analysis of 147,000 European children[J]. J Allergy Clin Immunol,2014,133(5): 1317-1329.
[30] Huang L, Chen Q, Zhao Y, et al. Is elective cesarean section associated with a higher risk of asthma A meta-analysis[J]. J Asthma,2015,52(1): 16-25.
[31] 慢性阻塞性肺疾病诊治专家组.祛痰/抗氧化药治疗慢性阻塞性肺疾病中国专家共识[J].国际呼吸杂志,2015,35(16):1201-1209.

2015年呼吸系统疾病研究进展

Clinical advances in pulmonary during 2015

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘蕾, 李明武, 万荣. 肺结核合并肺栓塞患者实验室指标的诊断价值[J]. 临床荟萃, 2024, 39(2): 134-139.
[2]	王沁濡, 尹琴, 李娟, 甘洪玉. 中医药治疗慢性阻塞性肺疾病合并肺动脉高压的研究进展[J]. 临床荟萃, 2024, 39(2): 188-192.
[3]	王琦, 陈宏. 维生素D在支气管哮喘和慢性阻塞性肺疾病治疗中的应用进展[J]. 临床荟萃, 2024, 39(1): 88-91.
[4]	武颖颖, 孔维香. 端粒及端粒酶逆转录酶基因与慢性阻塞性肺疾病相关性的研究进展[J]. 临床荟萃, 2023, 38(8): 749-752.
[5]	张莹, 涂平华, 吴展陵. 慢性阻塞性肺疾病表型的研究进展[J]. 临床荟萃, 2023, 38(4): 377-380.
[6]	郑志璇, 平芬, 李萍, 吴国飘. 阻塞性睡眠呼吸暂停低通气综合征与支气管哮喘关系的研究进展[J]. 临床荟萃, 2023, 38(10): 940-943.
[7]	王雪峰. 中度稳定期慢性阻塞性肺疾病疲劳与多维度指标的关系[J]. 临床荟萃, 2022, 37(8): 704-707.
[8]	张志萍, 张宝民, 秦伟, 高凌杰, 陈冬. 肠内营养支持对慢性阻塞性肺病急性加重期机械通气患者营养和预后的影响[J]. 临床荟萃, 2022, 37(6): 510-514.
[9]	王娇燕, 章迎春, 任珂明, 马国峰, 应可净. 奥氮平使用合并静脉血栓栓塞症16例临床分析[J]. 临床荟萃, 2022, 37(12): 1108-1113.
[10]	吴锦秀, 苗健龙. 抗MDA5抗体阳性皮肌炎合并间质性肺病的研究进展[J]. 临床荟萃, 2022, 37(11): 1048-1052.
[11]	侯伟, 张丽君, 张曼, 王亚坤, 田利远. 河北省南部地区住院患儿腺病毒呼吸道感染流行病学调查[J]. 临床荟萃, 2022, 37(10): 916-920.
[12]	田玉静, 李萍, 黄家容, 张宁, 平芬. 运动训练在慢性阻塞性肺疾病肺康复中的应用[J]. 临床荟萃, 2021, 36(9): 861-864.
[13]	付群, 郭迪, 赵文飞. 哮喘-慢阻肺重叠、哮喘和慢性阻塞性肺疾病患者诱导痰VEGF、ICAM-1、IL-13、呼出气一氧化氮水平的变化及临床意义[J]. 临床荟萃, 2021, 36(6): 513-516.
[14]	崔璐, 李静, 刘宇宏. 原发性干燥综合征并发肺栓塞1例并文献复习[J]. 临床荟萃, 2021, 36(4): 361-364.
[15]	杨林红, 钱宝堂, 郝应禄, 李燕萍, 赵静思. 与心脏疾病相关的肺栓塞临床研究现状[J]. 临床荟萃, 2021, 36(3): 285-288.